Monte Rosa Therapeutics, Inc.

AbbVie, Biogen, Pfizer and Novartis have each signed collaborations with biotechs centered on molecular glue degradation in fields such as cancer, immunology and neurology in just the past five months

Who : AbbVie and Neomorph What: The two companies have signed a collaboration and option-to-license deal to develop molecular glue degraders in oncology and immunology. Why: The deal brings togeth

Pharma executives no longer ask whether AI is important in their industry – that much is certain, and it is already ubiquitous. As Lamine Mbow , global head of discovery research at Boehringer Ingelh

Venture capital mega-rounds of $100m or more have surged in 2024 and the trend has continued in December, with announcements on 19 December that Ottimo Pharma’s series A round brought in more than $14